Ocera to Present at the JMP Securities Life Sciences ConferenceCompany presentation scheduled for June 22, 2016 at 11:00 AM ET
PALO ALTO, CA and RESEARCH TRIANGLE PARK, N.C. – June 13, 2016 – Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the JMP Securities Life Sciences Conference being held at the St. Regis in New York, New York from June 21-22, 2016. Ocera's presentation will take place on Wednesday, June 22, 2016 at 11:00 AM Eastern Time.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 60 days following the conference for those unable to listen live.
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
Ocera Therapeutics, Inc.